TB-500 Research Findings, Tagged by What Was Actually Tested

Thymosin Beta-4: The Parent Protein Behind TB-500

Most TB-500 research is, strictly, thymosin beta-4 research. Thymosin beta-4 is a ubiquitous 43-residue actin-sequestering peptide present in nearly all human cells and released by platelets and macrophages at sites of injury ^[5]. A review consolidated its profile: it binds actin and promotes cell mobilization and migration, decreases myofibroblast number to reduce scar formation, limits apoptosis and inflammation after injury, and promotes angiogenesis — the rationale behind clinical trials in dermal wounds, corneal injury and cardiac and CNS repair ^[5].

TB-500 is the actin-binding fragment of that protein. The findings below are organized by what each study administered. Where a result came from the full-length protein, it stays in the full-length column; the fragment's human efficacy is not established ^[10].

TB-500 Benefits Reported in Preclinical Studies

The reported benefits are preclinical and, in the load-bearing studies, generated with full-length Tβ4. In a rat full-thickness wound model, Tβ4 raised re-epithelialization by 42% at four days and up to 61% at seven days versus saline, increased wound contraction by at least 11% by day seven, and raised collagen deposition and angiogenesis ^[7]. Thymosin beta-4 enhanced medial collateral ligament healing in a rat model — one of the few direct connective-tissue findings underpinning athletic interest ^[5]. Nanomolar Tβ4 stimulated hair-follicle bulge stem cells and accelerated hair growth in rodents ^[5].

These are animal outcomes for the parent protein. They are not demonstrated human effects of the 7-mer, and the 2026 Sports Medicine review flagged exactly this evidence gap for the unapproved peptide class ^[11].

What is TB-500 used for in research?

In animal and in-vitro models, thymosin beta-4 is studied for tissue repair, wound re-epithelialization, angiogenesis, cardiac and neurological recovery, and anti-fibrotic effects ^[5]. The isolated fragment's human efficacy is unproven ^[10]. Research interest in TB-500 specifically derives from the fact that the 7-mer carries the protein's actin-binding motif, which is the upstream regulator of the cell-migration processes those repair models depend on ^[1]. The figures behind these models — and the TB-500 dosage in the research that produced them — are species-specific study parameters, not human protocols.

Does TB-500 help wound healing?

Full-length thymosin beta-4 accelerated re-epithelialization, contraction and collagen deposition in animal wound models, raising re-epithelialization 42% by day four and up to 61% by day seven in rats ^[7]. A synthetic peptide containing the actin-binding domain reproduced some of this activity in diabetic and aged mice ^[3]. Human efficacy of the fragment remains unproven ^[10].

How long does it take for TB-500 to work?

No human healing-timeline data exist for the fragment ^[10]. In a rat full-thickness wound model, full-length Tβ4 raised re-epithelialization 42% by day four and up to 61% by day seven ^[7]. That is an animal timeline for the parent protein, not a human schedule for the 7-mer, and it should not be read as one.

Does TB-500 affect the heart?

In rodents, thymosin beta-4 activated PINCH–integrin-linked-kinase–Akt survival signaling, promoted cardiac and endothelial cell migration, and improved cardiac function after coronary artery ligation ^[6]. The cardiac result is one of the strongest in the literature — but it is a full-length-protein, rodent finding, and the picture is mixed: systemic Tβ4 failed to attenuate myocardial ischemia-reperfusion injury in a porcine study, so the cardiac record is not uniformly positive.

Does TB-500 have neuroprotective effects?

In a rat embolic middle-cerebral-artery-occlusion model, intraperitoneal thymosin beta-4 at 2 and 12 mg/kg improved neurological function significantly from day 14 through day 56, while 18 mg/kg gave no significant benefit — a non-monotonic dose-response, with a modeled optimal near 3.75 mg/kg ^[8]. A companion report likewise found improved functional neurological outcome after embolic stroke ^[9]. These are rodent findings for the full-length protein; no human neuro trials of the fragment exist.

Does TB-500 promote angiogenesis?

Thymosin beta-4 promotes endothelial migration and new-vessel formation, part of its repair profile ^[5]. The same pro-angiogenic activity is also part of the tumor safety concern, because angiogenesis supports tumor growth as well as wound healing. The mechanism cuts both ways, which is why this finding appears in both the benefits and the safety reading.

Does TB-500 work for muscle tears and recovery?

Thymosin beta-4 acts as a myoblast chemoattractant in injury models. But in dystrophin-deficient (mdx) mice, chronic dosing at 150 µg twice weekly for six months increased the number of regenerating fibers without improving muscle strength, cardiac function or fibrosis — a notable null functional result that tempers the recovery narrative. No controlled human recovery trials of the fragment exist ^[10].

Does TB-500 reduce inflammation?

Thymosin beta-4 suppressed TNF-α-induced NF-κB activation and IL-8 in vitro, and a 2024 study linked it to pro-resolving inflammation pathways ^[12]. These are mechanistic and animal findings for the parent protein, not human anti-inflammatory claims for the 7-mer.

Does TB-500 increase hair growth?

Nanomolar thymosin beta-4 stimulated hair-follicle bulge stem cells and accelerated hair growth in rats and mice ^[5]. These are animal results for the full-length protein. They are not demonstrated human effects of the TB-500 fragment.

Does TB-500 cause cancer or promote tumor growth?

Thymosin beta-4 is overexpressed in several cancers — pancreatic and colorectal among them — and is implicated in metastasis and tumor angiogenesis. The same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression ^[5]. This is the principal hard safety caveat in the literature, and it is an open concern rather than a resolved risk estimate.

TB-500 Side Effects and the Tumor/Angiogenesis Safety Signal

No controlled human safety data exist for the TB-500 fragment ^[10]. The principal theoretical concern is the tumor/angiogenesis signal: a peptide that promotes cell migration and new-vessel formation could, in principle, favor tumor progression as readily as wound repair ^[5]. The 2026 Sports Medicine review noted that unapproved peptides in this class carry potential for serious harm and operate largely outside regulatory oversight ^[11]. The compound's WADA prohibited status is a separate, settled fact that sits beside these open safety questions.

Two further unknowns belong on the record. Research-grade material quality is a recurring concern — peptide identity, purity and correct sequence (full-length versus fragment) are not guaranteed in unregulated supply, which also complicates interpreting anecdotal results. And community "loading then maintenance" protocols have no basis in controlled human trials. The non-monotonic stroke dose-response (benefit at 2 and 12 mg/kg, none at 18 mg/kg) directly undermines the "more is better" logic those loading schemes assume ^[8].

What are the side effects of TB-500?

No controlled human safety data exist for the fragment ^[10]. The principal theoretical concern is the tumor/angiogenesis signal — the same pro-migratory, pro-angiogenic activity that aids repair could favor tumor progression ^[5]. Research-grade material purity and identity (fragment versus full-length) are additional unknowns that complicate any safety reading.

Is TB-500 Safe? The State of the Human Safety Data

There is no completed human safety trial of the TB-500 heptapeptide for any indication ^[10]. The only human safety data are for full-length Tβ4: a randomized, placebo-controlled Phase 1 intravenous study in 40 healthy volunteers found it well tolerated up to 1260 mg, with no dose-limiting toxicities or serious adverse events ^[10]. That tolerability finding is for the protein, not the fragment, and it does not establish safety for the 7-mer in any route or population.

Are there any human clinical trials on TB-500?

There are no completed controlled trials of the TB-500 fragment ^[10]. Human data exist only for full-length Tβ4 — a randomized Phase 1 intravenous safety and pharmacokinetic study in healthy volunteers, and topical ophthalmic Tβ4 (RGN-259) dry-eye trials ^[10]. Injectable Tβ4 stroke and acute-MI trials were registered; an early injectable trial was withdrawn, so a presumed clinical pipeline overstates the current evidence.

Can TB-500 help with tendon and ligament injuries?

Thymosin beta-4 enhanced medial collateral ligament healing in a rat model — one of the few direct connective-tissue findings underpinning athletic interest in the compound ^[5]. This has not been confirmed in controlled human studies, and it was the full-length protein, not the fragment, that produced the result ^[10].

What is the difference between TB-500 and BPC-157?

They are distinct research peptides studied for tissue repair via different mechanisms — TB-500 via the thymosin beta-4 actin-binding motif ^[1]. Both are unapproved for human use, and both were flagged in the 2026 Sports Medicine review for scarce human safety data ^[11]. The comparison below sets out how they differ on the record.

TB-500 and BPC-157: How They Differ in the Research

TB-500 and BPC-157 are two separate research peptides, often discussed together because both are studied for tissue repair — but their mechanisms and evidence bases differ. TB-500 is the Ac-LKKTETQ actin-binding fragment of thymosin beta-4, and its mechanistic story runs through G-actin sequestration and cell migration ^[1][2]. BPC-157 is a separate 15-amino-acid peptide with its own distinct literature; this site does not summarize it.

What they share on the regulatory record is more concrete than any claimed synergy: both appear in the FDA's 503A nominated-substances framework, and the 2026 Sports Medicine review lists both among unapproved peptides whose human safety data are scarce ^[11]. No controlled human trial has tested the two together, so any combination claim is, on the evidence, unfilled. The honest comparison is that each has a single-compound literature and neither has the human outcome data that would let a reader rank one against the other for any human use.